Poisson regression analysis of asthma mortality and hospitalizations by age group, associated with the sales of ICS and SABA*
| Health outcome | Model 1† | Model 2 (Model 1+SABA)‡ | ||||
|---|---|---|---|---|---|---|
| ICS | SABA | ICS | ||||
| β1 | p value | β2 | p value | β1 | p value | |
| *All models included an adjustment for extra-Poisson due to year to year variability. | ||||||
| †Model 1: Mortality: log (expected number of age-specific deaths due to asthma) = β0 × log (age specific population size) + β1 × steroids. Hospital admissions: log (expected number of age specific hospital admissions due to asthma) = β0 × log (age specific population size) + β1 × ICS. Thus, exp(β1×10 000) is the rate ratio of asthma mortality/hospital admissions per 10 000 units of medication sold. | ||||||
| ‡exp(β1×10 000) of ICS in model 2 is the adjusted rate ratio of asthma mortality/hospital admissions per 100 000 units of medication sold when SABA sales are held constant. | ||||||
| Asthma mortality | ||||||
| 5–34 years | −0.0029 | 0.0179 | −0.0002 | 0.2782 | −0.0030 | 0.0394 |
| 35–64 years | −0.0023 | 0.0098 | 0.0023 | 0.2351 | −0.0046 | 0.0431 |
| 5–64 years | −0.0023 | 0.0196 | 0.0002 | 0.1826 | −0.0037 | 0.0461 |
| Hospital admissions for asthma | ||||||
| 0–14 years | −0.0039 | 0.0003 | 0.0003 | 0.1676 | −0.0041 | 0.0004 |
| 15+ years | −0.0014 | 0.0030 | −0.0003 | 0.1515 | −0.0013 | 0.0165 |
| All ages | −0.0024 | 0.0002 | −0.0771 | 0.0529 | −0.0024 | 0.0006 |